...
首页> 外文期刊>British Journal of Haematology >BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma.
【24h】

BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma.

机译:IGK基因重排的BIOMED-2 PCR分析对于滤泡性淋巴瘤B细胞克隆性分析至关重要。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

B-cell clonality analysis is commonly performed by polymerase chain reaction (PCR) targeting the IGH genes although a high false-negative rate is recognized for germinal centre/post-germinal centre B-cell malignancies, especially follicular lymphoma. We assessed the diagnostic value of BIOMED-2 IGK assays and investigated the cause of IGH PCR failure in 77 patients with follicular lymphoma. Using the full set of BIOMED-2 reactions, clonal immunoglobulin gene rearrangements were detected in 74 (96%) cases. The clonality detection rate was 86% by two IGK reactions but only 68% by five IGH reactions (P < 0.001). Sequencing of the clonal PCR products showed significantly fewer somatic mutations in the rearranged IGKV (9/27 cases, 33%, mean mutation rate 0.5%) than IGHV (17/17 cases, 100%, rate 11.0%) (P < 0.01). All IGHV-IGHJ PCR failures occurred in cases with at least one mutation at the corresponding IGHV primer binding sites. t(14:18)(q32:q21)/IGH-BCL2 was detected in 50 of 71 (70%) cases and the presence of the translocation was not associated with the poor performance of IGH assays. Our results showed that BIOMED-2 IGK assays are significantly more sensitive than IGH assays in follicular lymphoma due to the fact that the rearranged IGKV is less frequently targeted by somatic hypermutation than IGHV, and therefore, are essential in routine clonality analysis of these lymphomas.
机译:B细胞克隆性分析通常通过针对IGH基因的聚合酶链反应(PCR)进行,尽管对于生发中心/生后中心B细胞恶性肿瘤(尤其是滤泡性淋巴瘤),公认的假阴性率很高。我们评估了BIOMED-2 IGK分析的诊断价值,并调查了77例滤泡性淋巴瘤患者IGH PCR失败的原因。使用全套BIOMED-2反应,在74(96%)例中检测到了克隆性免疫球蛋白基因重排。两个IGK反应的克隆性检测率为86%,但是五个IGH反应的克隆性检测率为68%(P <0.001)。克隆PCR产物的测序表明,重排IGKV的体细胞突变(9/27例,33%,平均突变率0.5%)比IGHV(17/17例,100%,比率11.0%)显着更少(P <0.01) 。所有IGHV-IGHJ PCR失败均发生在相应IGHV引物结合位点发生至少一个突变的情况下。在71例病例中有50例(70%)中检测到了t(14:18)(q32:q21)/ IGH-BCL2,易位与IGH检测的不良表现无关。我们的结果表明,在滤泡性淋巴瘤中,BIOMED-2 IGK检测比IGH检测要敏感得多,这是因为与IGHV相比,重排的IGKV较少受到体细胞高变的靶向,因此在这些淋巴瘤的常规克隆分析中必不可少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号